IDEXX Laboratories, Inc. (IDXX) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $567.83, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Thin upside margin: 8.7%.
IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in... Read more
Hold if already holding. Not a fresh buy at $567.83, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Thin upside margin: 8.7%. Chart setup: Death cross but MACD improving, RSI 55. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, positive momentum, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — IDEXX Laboratories, Inc.
Latest news
- NEWS Transamerica Mid Cap Growth's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus — GuruFocus neutral
- NEWS IDEXX Laboratories Shares Surge 7% After Beating Q3 Estimates on Strong Diagnostic Demand - MSN — MSN positive
- NEWS Bank of America Securities Remains a Hold on Idexx Laboratories (IDXX) - The Globe and Mail — The Globe and Mail neutral
- NEWS Sanctuary Advisors LLC Purchases 7,186 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat — MarketBeat positive
- NEWS Comerica Bank Sells 9,639 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierOrtho-Clinical Diagnostics10-K Item 1: 'We are obligated to purchase all of our requirements for our current menu of Catalyst chemistry slides from Ortho to the extent Ortho is able to supply those requirements'
Material Events(8-K, last 90d)
- 2026-03-26Item 5.02MEDIUMEVP Nimrata Hunt mutually agreed to cease as EVP Global Strategy and Commercial effective April 13, 2026, with advisory services through July 13, 2026. No named replacement for the role; no disagreement cited.SEC filing →
- 2026-02-13Item 5.02LOWDirector M. Anne Szostak notified IDEXX of her intention to retire from the Board effective immediately following the 2026 Annual Meeting (May 12, 2026). No disagreement with company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $567.83, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Thin upside margin: 8.7%. Chart setup: Death cross but MACD improving, RSI 55. Maintain position. Not compelling to add more. Target $616.95 (+8.7%), stop $535.97 (−5.9%), A.R:R 1.4:1. Score 5.6/10, moderate confidence.
Take-profit target: $616.95 (+8.7% upside). Target $616.95 (+8.7%), stop $535.97 (−5.9%), A.R:R 1.4:1. Stop-loss: $535.97.
Concentration risk — Supplier: Ortho-Clinical Diagnostics; Thin upside margin: 8.7%; Expensive valuation.
IDEXX Laboratories, Inc. trades at a P/E of 41.3 (forward 34.0). TrendMatrix value score: 3.4/10. Verdict: Hold.
22 analysts cover IDXX with a consensus score of 4.0/5. Average price target: $709.
What does IDEXX Laboratories, Inc. do?IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments,...
IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in 2025, with highly recurring revenue from consumables and subscriptions sold direct to veterinarians in the U.S. and internationally.